Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Triple Therapy for Type 1 Diabetes With Insulin, Semaglutide, and Dapagliflozin

NCT03899402 is registered in ClinicalTrials.gov with State University of New York at Buffalo as lead sponsor.

NCT NCT03899402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03899402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Triple Therapy for Type 1 Diabetes With Insulin, Semaglutide, and Dapagliflozin
Lead sponsor
State University of New York at Buffalo
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
May 1, 2019
Completion date
June 30, 2026
Enrollment
78 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes mellitus